Journal article

Renin-angiotensin system inhibition and risk of infection and mortality in COVID-19: a systematic review and meta-analysis

Anoop N Koshy, Alexandra C Murphy, Omar Farouque, Jay Ramchand, Louise M Burrell, Matias B Yudi

Internal Medicine Journal | WILEY | Published : 2020

Abstract

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, enters human cells by binding of its viral protein to the aminopeptidase angiotensin-converting enzyme 2 (ACE2). This has led to speculation whether treatment with renin-angiotensin system (RAS) inhibitors was associated with an increased likelihood of a positive test for COVID-19 and risk of mortality. AIMS: We performed a systematic review and meta-analysis to investigate whether RAS inhibitors increased the likelihood of a positive test or death/severe illness in patients with COVID-19. METHODS: A systematic search of MEDLINE, PubMed and EMBASE was conducted for studies stratified by..

View full abstract

Grants

Awarded by Royal Australasian College of Physicians Blackburn Scholarship


Funding Acknowledgements

A. N. Koshy is a recipient of the National Health and Medical Research Council of Australia/National Heart Foundation Post-Graduate Scholarship and Royal Australasian College of Physicians Blackburn Scholarship (1150874). A. C. Murphy is supported by the Cardiac Society of Australia and New Zealand PhD Scholarship.